An oncological view on the blood-testis barrier

被引:146
作者
Bart, J
Groen, HJM
van der Graaf, WTA
Hollema, H
Hendrikse, NH
Vaalburg, W
Sleijfer, DT
de Vries, EGE
机构
[1] Univ Groningen Hosp, Dept Med Oncol, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen Hosp, Dept Internal Med, NL-9700 RB Groningen, Netherlands
[3] Univ Groningen Hosp, PET Ctr, NL-9700 RB Groningen, Netherlands
[4] Univ Groningen Hosp, Dept Pathol, NL-9700 RB Groningen, Netherlands
关键词
D O I
10.1016/S1470-2045(02)00776-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The function of the blood-testis barrier is to protect germ cells from harmful influences; thus, it also impedes the delivery of chemotherapeutic drugs to the testis. The barrier has three components: first, a physicochemical barrier consisting of continuous capillaries, Sertoli cells in the tubular wall, connected together with narrow tight junctions, and a myoid-cell layer around the seminiferous tubule. Second, an efflux-pump barrier that contains P-glycoprotein in the luminal capillary endothelium and on the myoid-cell layer; and multidrug-resistance associated protein 1 located basolaterally on Sertoli cells. Third, an immunological barrier, consisting of Fas ligand on Sertoli cells. Inhibition of P-glycoprotein function offers the opportunity to increase the delivery of cytotoxic drugs to the testis. In the future, visualisation of function in the blood-testis barrier may also be helpful to identify groups of patients in whom testis conservation is safe or to select drugs that are less harmful to fertility.
引用
收藏
页码:357 / 363
页数:7
相关论文
共 78 条
[1]   Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC833 (Valspodar) [J].
Advani, R ;
Saba, HI ;
Tallman, MS ;
Rowe, JM ;
Wiernik, PH ;
Ramek, J ;
Dugan, K ;
Lum, B ;
Villena, J ;
Davis, E ;
Paietta, E ;
Litchman, M ;
Sikic, BI ;
Greenberg, PL .
BLOOD, 1999, 93 (03) :787-795
[2]   Death receptors: Signaling and modulation [J].
Ashkenazi, A ;
Dixit, VM .
SCIENCE, 1998, 281 (5381) :1305-1308
[3]  
Baer MR, 1999, BLOOD, V94, p383A
[4]   The blood-brain barrier and oncology: new insights into function and modulation [J].
Bart, J ;
Groen, HJM ;
Hendrikse, NH ;
van der Graaf, WTA ;
Vaalburg, W ;
de Vries, EGE .
CANCER TREATMENT REVIEWS, 2000, 26 (06) :449-462
[5]  
BART J, 2001, P ASCO, V20, pA73
[6]  
Bechmann I, 1999, GLIA, V27, P62, DOI 10.1002/(SICI)1098-1136(199907)27:1<62::AID-GLIA7>3.0.CO
[7]  
2-S
[8]   IMMUNOHISTOCHEMICAL CHARACTERIZATION OF SEMINOMA AND ITS INFLAMMATORY CELL INFILTRATE [J].
BELL, DA ;
FLOTTE, TJ ;
BHAN, AK .
HUMAN PATHOLOGY, 1987, 18 (05) :511-520
[9]   A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION [J].
BELLGRAU, D ;
GOLD, D ;
SELAWRY, H ;
MOORE, J ;
FRANZUSOFF, A ;
DUKE, RC .
NATURE, 1995, 377 (6550) :630-632
[10]   EFFECT OF TREATMENT ON FERTILITY AND SEXUAL FUNCTION IN MALES WITH METASTATIC NONSEMINOMATOUS GERM-CELL TUMORS OF TESTIS [J].
BRENNER, J ;
VUGRIN, D ;
WHITMORE, WF .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1985, 8 (02) :178-182